Author

Mara Sadanowicz

Observed name: M. Sadanowicz

Institutions: Boston Children's Hospital, Harvard University, Johns Hopkins University, Pfizer (United States), Scholar Rock (United States), TG Therapeutics, Inc. (United States), The University of Texas Southwestern Medical Center, Stanford University

Observed institutions: Boston Children's Hospital, Harvard University, Johns Hopkins University, Pfizer (United States), Scholar Rock (United States), Karyopharm Therapeutics (United States), TG Therapeutics, Inc. (United States), The University of Texas Southwestern Medical Center, Stanford University

ORCID: 0009-0005-0322-1110

Observed ORCID: 0009-0005-0322-1110

OpenAlex ID: A5037213636

Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ Study

2024 · Thomas O. Crawford, Basil T. Darras, et al. · Neurology · 61

Phase 2 results of selinexor in advanced de-differentiated (DDLS) liposarcoma (SEAL) study: A phase 2/3, randomized, double blind, placebo controlled cross-over study.

2018 · Mrinal M. Gounder, Neeta Somaiah, et al. · Journal of Clinical Oncology · 22

SMA - TREATMENT

2021 · A. Place, D. Barrett, et al. · Neuromuscular Disorders · 2

Treatment Effects Among Patients with Type 2 and Type 3 SMA Directly Reported by Patients and Caregivers from the TOPAZ Clinical Trial (P2-8.010)

2023 · Robin Pokrzywinski, Katelyn Cutts, et al. · Neurology · 1

P234 Effect of Apitegromab on pedi-cat and promis-fatigue questionnaire at 36-months in patients with spinal muscular atrophy

2023 · T. Crawford, B. Darras, et al. · Neuromuscular Disorders

Relationship of pharmacokinetics and pharmacodynamics to apitegromab efficacy in patients with later-onset spinal muscular atrophy (Types 2 and 3 SMA): Results from the TOPAZ study

2021 · Thomas Crawford, Amy Place, et al. · Journal of the Neurological Sciences

Works count: 6

Citation count: 86

H-index: 2

I10-index: 2